EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 20, 2005--BioTime, Inc. (OTCBB:BTIM) announced today that it has entered into an addendum to its agreement with Summit Pharmaceuticals International Corporation to develop Hextend(R) and PentaLyte(R) for the Japanese market. The addendum grants Summit the licenses required to permit Summit to implement an agreement with Maruishi Pharmaceutical Co., Ltd., to seek regulatory approval and to manufacture and market Hextend(R) in Japan. Summit will also participate in the regulatory approval process and will have the right to manufacture and market Hextend(R) in Japan if regulatory approval is obtained.
